Enhertu Comparison in HER2-Low Breast Cancer Treatment - Caracas

The US Food and Drug Administration gave new approval to the medication Enhertu for the treatment of HER2-Low breast cancer, a difficult-to-treat subtype of breast cancer. The drug, Enhertu 100 mg injection mainly combines 2 potent medicines to attack malignant cells without causing harm to normal cells. In conducted clinical trials, patients who were treated with Enhertu significantly survived for an average of 23.9 months in comparison to 16.8 months for patients who were treated with chemotherapy alone. This is the first therapy approved for HER2-low breast cancer and will significantly provide an important new targeted therapeutic option for several patients. Kindly Call or WhatsApp: +91 9310090915 to know more about HER2-low breast cancer treatment, cost, and treatment availability.